Nebulised drug therapy may be less effective dose inhalers, rather than nebulisers.
14 These are attached to an adapter in the ventilator in patients undergoing mechanical ventilation than in those spontaneously breathing for two circuit and actuated during lung inflation. The method is simple and treatments can be admain reasons -firstly, ventilated patients often have severe lung disease associated with airway ministered rapidly. The amount of drug reaching the lungs has been estimated as 1.5-2% in plugging and collapsed segments which limit the spread of aerosols to affected areas, and infants 12 15 and 3.9-5.6% in adults. 16 17 Administration using a metered dose inhaler is secondly, aerosol deposition from nebulisers and metered dose inhalers is reduced during increased by using an aerosol holding chamber 17 and this method may be more efficient mechanical ventilation compared with spontaneous breathing.
1 This is due to a number of than using an inspiratory phase activated jet nebuliser. 16 Arnon et al 18 found that the use of factors including the site of the nebuliser in the ventilator circuit, the ventilator settings, the a metered dose inhaler and an Aerochamber (MV15, Trudell Medical, Canada), attached method of triggering of the nebuliser, and the size of the endotracheal tube. The indications between the Y piece and the endotracheal tube, delivered larger amounts of budesonide to a for nebuliser therapy in mechanically ventilated patients are given in table 1.
filter in an in vitro ventilator circuit than either an MAD2 nebuliser or an Ultravent nebuliser. In ventilated patients compliance is not a problem and it is not necessary for nebulised Another study in ventilated patients with airways obstruction has shown that a 270 g dose treatments to be completed rapidly. Indeed, continuous nebulisation may be appropriate of salbutamol given via a metered dose inhaler produces a similar increase in passive expiratory for some conditions so nebulisers need not be selected on the basis of rapid output char-flow rate to that produced by a 2.5 mg dose given by a jet (Upmist) nebuliser. 19 acteristics.
Jet nebulisers tend to leak around their joinThe factors which appear to increase aerosol delivery to the mechanically ventilated patient ing parts, especially when used in conjunction with a ventilator. The back pressure necessary from metered dose inhalers are the use of a holding chamber, 17 18 20 locating the metered to cause leaks should be documented by the manufacturer and users should be encouraged dose inhaler adapter on the inspiratory limb of
Departments of
to use systems which do not leak. There is also the circuit rather than immediately adjacent Nuclear Medicine, a need to determine the nebuliser outputs and to the endotracheal tube, 17 during mechanical ventilation using metered nebulisers are widely available and cheap, but many are not designed for use during ventilation and leak, particularly at high inflation adults. 16 25-27 In vivo data are lacking in infants. ticle drying tube, is clinically proven although propriate for mechanically ventilated patients: deposition associated with this apparatus is 1. Administration by metered dose inhaler into unknown and delivery in vitro is poor. a spacer connected to the inspiratory limb of Several factors may improve aerosol delivery the ventilator circuit with actuation at the onset to the mechanically ventilated subject from jet of lung inflation. Humidification should be nebulisers. Placing the nebuliser in the in-interrupted for a few minutes before adspiratory limb of the ventilator circuit rather ministration. than at the catheter mount connection or on the 2. Use of an inspiratory phase activated jet expiratory limb increases delivery. 28 29 However, nebuliser connected to an aerosol holding placing the nebuliser too far from the patient chamber placed on the inspiratory limb of the (>30 cm) may increase deposition on the circuit circuit, or at least connected by a T piece in and reduce delivery. 30 Delivery is also increased the inspiratory tubing no more than 30 cm from by inspiratory triggered nebulisation, 29 in-the Y piece. A high nebuliser gas flow should creasing the fill in the nebuliser, 27 interrupting be used and the drug solution should be diluted humidification during nebulisation, 22 31 and at-to fill the nebuliser to capacity. Humidification taching the nebuliser to a spacer in the in-should be discontinued for a few minutes before spiratory limb. 25 27 28 Alteration of the ventilator and throughout nebulisation. settings also affects deposition which is in-3. Use of an ultrasonic nebuliser connected to creased by decreasing the respiratory rate, in-the inspiratory limb of the circuit. The drug creasing the inspiratory time, and by decreasing solution should be diluted to fill the nebuliser minute ventilation. 25 27 28 In spontaneously to capacity and humidification should be disbreathing subjects the use of positive end-ex-continued for a few minutes before and piratory pressure (PEEP) can increase the im-throughout nebulisation. provements in lung function provided by inhaled salbutamol, 32 but use during mechanical ventilation will increase peak airways Clinical evidence of benefit from drug pressure and may also worsen air trapping aerosols associated with severe bronchospasm. 33 Small Evidence that can be used in assessing the particles are associated with increased penpotential value of nebulised therapy in ventiletration of endotracheal tubes 34 and nebulisers ated patients, in order of importance, is as which produce these may be associated with follows: 37 (1) clinical trials using clinically relhigher pulmonary deposition. 35 evant end points such as survival, length of stay in ITU, length of stay in hospital; (2) clinical trials using physiological measurements such   as changes in airway resistance or lung comUltrasonic nebulisers can be used during all pliance; (3) aerosol deposition and deposition types of mechanical ventilation. They are simpler to use than jet nebulisers as no gas flow measurements in vivo in man using radiois required and many have large capacities. labelled aerosols; (4) aerosol deposition measDisadvantages are that in theory some drugs urements in animals (these are particularly might not be stable during ultrasonic nebu-appropriate for paediatric studies although not lisation and the process may produce erroneous all lung conditions affecting infants can be automated measurements of tidal volume. Pul-mimicked in the lungs of healthy animals and, monary aerosol deposition in vivo associated furthermore, the airway structure of animals with ultrasonic nebulisers has been estimated differs from that of human infants and therefore as 1.3% in infants using the Penta-the distribution of aerosol may be different); sonic. In vivo data are lacking in adults but (5) aerosol delivery measurements made in vivo in vitro data indicate that delivery through by measuring urinary excretion of nebulised an endotracheal tube during volume cycled drugs although measurements may be affected ventilation can be as high as 22% using the by other factors such as renal or liver function; Samsonic ultrasonic nebuliser, an 18 ml fill (6) aerosol delivery measurements made in volume, and an aerosol storage chamber. 36 vitro or using combined in vivo/in vitro methods Under similar conditions the system 22 Acorn using radiolabelled or fluorescent aerosols. jet nebuliser delivers 10%. 28 These are inevitably overestimates of in vivo The factors that appear to improve aerosol lung deposition. delivery using ultrasonic nebulisers include plaAn ideal approach is a combination of these cing the nebuliser in the inspiratory limb of the methods. In vitro studies can select those nebuventilator circuit rather than at the catheter lisers worthy of consideration for delivering a mount connection or on the expiratory limb, 26 particular drug, and then deposition and clinincreasing the fill in the nebuliser, 28 36 attaching ical outcome can be demonstrated in a parthe nebuliser to a spacer in the inspiratory ticular clinical situation. The amount of drug limb, 28 36 and alteration of the ventilator settings deposited is estimated to prove that sufficient -for example, decreasing the respiratory rate, drug is being deposited for clinical benefit. increasing the inspiratory time, or decreasing There are few published studies proving the the minute ventilation.
36 Drugs have to be efficacy of aerosol drug treatments in ventilated shown to be stable during ultrasonic nebupatients and it is often necessary to make clinlisation.
ical judgements on the need for aerosol therapy using clinical trial data from spontaneously breathing subjects. This information is used, Recommended practice together with lung deposition or delivery data Any of the following three methods of aerosol administration currently appear to be ap-from patients receiving mechanical ventilation, to use, is an inefficient method for delivering aerosol (0.1 l/min) compared with other methods and its particle size output is comparatively large (mass median aerodynamic diato try and predict the usefulness of treatment. Apparatus for which there are research data on meter (MMAD) 6.8 m). 45 Other devices may be better for delivering tribavirin but this has delivery or lung deposition during mechanical ventilation are shown in table 2.
yet to be proved. Tribavirin may deposit in ventilator circuits and block the expiratory valve, leading to expiratory pressures and barotrauma. This should  Nebulised 2 agonists are effective for acute be avoided by appropriate use of filters to protect the ventilator from the effects of the severe asthma in spontaneously breathing patients 38 and their use during mechanical vent-aerosol. ilation can also improve measurements of pulmonary function (respiratory system resistance, compliance) in adults 1 2 39 and infants 3 with   acute asthma, although not all studies have Nebulised beclomethasone 50 g eight hourly shown this. 40 Pulmonary function can also be for 28 days reduced airways resistance and improved in adults with chronic obstructive increased dynamic compliance in infants with pulmonary disease. Beclomethabeen performed to compare different broncho-sone was administered using a Whisper dilators or methods of aerosol administration. (Marquest Medical Products, Englewood, CoIn some patients delivery of aerosol to peri-lorado, USA) jet nebuliser on the inspiratory pheral bronchioles may be particularly poor limb of the circuit and running at 4-8 l/min of because of intense bronchospasm and it may humidified gas. Pulmonary deposition was not often be appropriate to use intravenous as well measured.
Beclomethasone dipropionate as inhaled bronchodilators in patients with nebuliser solution is no longer produced but it severe disease.
is to be expected that beclomethasone delivered Ipratropium bromide also improves pul-by metered dose inhaler or an alternative nebumonary function in mechanically ventilated lised steroid such as budesonide should provide patients with COPD. 
   () 
Clinical trials have been performed in infants     with respiratory failure associated with RSV () infection, evaluating the efficacy of continuous Preliminary evidence suggests that nebulised nebulisation of tribavirin (20 mg/ml) using the colfosceril palmitate (40-80 mg) given con-SPAG. 43 This consists of a jet nebuliser coupled tinuously over five days may improve the alto a particle drying tube. In one study 5 infants veolar-arterial oxygen tension gradient treated with nebulised tribavirin had reduced (A-aD 2 ) and fractional inspired oxygen (F 2 ) durations of mechanical ventilation, oxygen and reduce mortality in adults with sepsistreatment, and hospital stay compared with induced ARDS. 9 Weg et al 8 also used nebulised infants treated with nebulised water. In a sec-colfosceril palmitate in a group of patients with ond study 44 infants treated with nebulised tri-ARDS for 12 or 24 hours per day and found bavirin had small reductions in the duration of a trend towards improvement in mortality commechanical ventilation, supplemental oxygen pared with no treatment. use, and hospital stay compared with those Nebulised orciprenaline (metaproterenol) receiving nebulised saline. However, the has been shown to reduce airways resistance differences were not statistically significant, al-in patients with ARDS. 46 though a clinically relevant drug effect may have been missed because of reduced study
